Pacira Pharmaceuticals, DPx’s Patheon Form Pact for New Sterile Manufacturing Suites
Pacira Pharmaceuticals, Inc. has formed a strategic co-production partnership with Patheon, the pharmaceutical services business owned by DPx Holdings B.V., to manufacture and package EXPAREL® (bupivacaine liposome injectable suspension) at Patheon's facility in Swindon, United Kingdom.
Under the co-production partnership agreements, Pacira and Patheon will collaborate to construct dedicated EXPAREL manufacturing suites in Patheon's specialty sterile manufacturing facility in Swindon. The first additional EXPAREL manufacturing suite at Patheon, which is expected to come on line in two to three years' time, will be designed to mirror the recently approved Suite C manufacturing facility at the Pacira Science Center Campus in San Diego, providing, at scale, approximately $300 million of additional product manufacturing capacity, or an aggregate $700 million worth of overall production capacity for EXPAREL. The design and production scale of the second additional manufacturing suite will be determined at a future date.
Patheon will be responsible for the construction of the dedicated manufacturing suites, installation, and validation of the manufacturing equipment and the commercial manufacture of EXPAREL.
Pacira will oversee the design and purchase of the dedicated EXPAREL manufacturing equipment to be installed in the Patheon facility, lead the technical transfer of the manufacturing process and govern, with on-site and other personnel, the oversight and optimization of the proprietary DepoFoam®-based manufacturing process.
Source: Pacira Pharmaceuticals
